XSHG
603811
Market cap473mUSD
Oct 09, Last price
7.07CNY
1D
2.17%
1Q
-3.28%
IPO
8.77%
Name
Zhejiang Cheng Yi Pharmaceutical Co Ltd
Chart & performance
P/E
16.60
P/S
3.99
EPS
0.43
Div yield, %
2.58%
Shrs. gr., 5y
-0.36%
Rev. gr., 5y
1.39%
Revenues
812m
+13.72%
Net income
195m
-2.78%
CFO
280m
+36.30%
Dividend
Jun 26, 20260.42 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs, injections, food, capsules, tablets, traditional Chinese medicines, preparations, pharmaceutical intermediates in China and internationally. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is based in Shanghai, China.
Key people
Zehui Ke
Deputy General Manager, Secretary of the Board · since 2019
Shisheng Li
Deputy General Manager, Director · since 2019
Zhidong Lu
Deputy General Manager · since 2019
Chunjian Zhao
General Manager, Director · since 2019
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||